[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uremic-toxins\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uremic-toxins":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627026","alterations-of-gut-derived-uremic-toxins-and-microbiome-metabolites-by-multispecies-synbiotic-100627026",false,"NCT07443280","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic Supplementation in Hemodialysis Patients","Inclusion Criteria:\n\n* Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months\n\nExclusion Criteria:\n\n1. Use of probiotic supplements within the last month;\n2. Hospitalization within the past month for acute infections or CKD-related complications;\n3. History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);\n4. Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;\n5. Use of antibiotics or immunosuppressive therapy within the preceding three months.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis frequently exhibit significant gut microbiota dysbiosis and increased intestinal permeability. These alterations enable the translocation of endotoxins and gut-derived uremic toxins-such as indoxyl sulfate and p-cresyl sulfate-into the systemic circulation, exacerbating systemic inflammation, elevating cardiovascular risk, and accelerating disease progression.\n\nMultispecies synbiotic supplementation has emerged as a promising intervention to restore gut microbial equilibrium, strengthen intestinal barrier function, and reduce the systemic load of harmful microbial metabolites. Through modulation of inflammatory pathways and reduction of circulating uremic toxins, synbiotic hold potential to improve clinical outcomes in this vulnerable population.\n\nAlthough preclinical and some clinical evidence suggests benefits of probiotic therapy, comprehensive clinical trials specifically examining multispecies synbiotic effects on gut inflammatory markers, gut derived metabolite profiles, and uremic toxin levels in hemodialysis patients remain limited. This pilot study aims to address this gap by investigating the biological and clinical effects of a 12-week multispecies regimen in adult maintenance hemodialysis patients.",[26,27,28],"Symbiotic","Uremic Toxins","Gut -Microbiota",[30,31,32,33],"multispecies synbiotic","uremic toxins","gut microbiome","hemodialysis patients","RECRUITING","2026-06-01",{"date":37,"type":38},"2026-06-03","ACTUAL",{"date":40,"type":38},"2026-05-04",{"date":42,"type":20},"2026-12-31",{"name":44,"class":45},"Tungs' Taichung Metroharbour Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":63,"locationsCount":46},"100628407","modulation-of-gut-microbiota-composition-and-gut-permeability-profiles-by-multispecies-synbiotic-supplementation-in-hemodialysis-patients-100628407","NCT07461233","Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients",{"count":19,"type":20},[23],"Chronic kidney disease (CKD) patients undergoing maintenance hemodialysis experience profound alterations in their gut microbiota, leading to dysbiosis and increased gut permeability. This disruption facilitates the translocation of endotoxins and gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate into the systemic circulation, contributing to heightened systemic inflammation, cardiovascular disease risk, and accelerated CKD progression.\n\nSynbiotic supplementation, particularly multispecies formulations, has emerged as a promising therapeutic strategy to restore gut microbial balance, enhance intestinal barrier integrity, and reduce the systemic burden of deleterious microbial metabolites. These probiotics potentially improve clinical outcomes by modulating inflammatory pathways and decreasing circulating levels of uremic toxins.\n\nDespite these insights, few clinical trials have comprehensively assessed the effects of multispecies synbiotic on fecal microbiome composition, gut permeability and uremic toxin profiles in hemodialysis patients. This pilot study aims to fill this gap by evaluating the modulatory effects of a 12-week multispecies synbiotic intervention.",[26,27,28,56,57],"Gut Permeability","Hemodialysis",[30,33,31,32,59],"gut permeability",{"date":37,"type":38},{"date":40,"type":38},{"date":42,"type":20},{"name":44,"class":45},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100582429","phase-1-probiotic-supplementation-and-disease-progression-in-ckd-a-randomized-trial-100582429","NCT06863194","Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial","Effects of Probiotic Supplementation on Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease: A Randomized Controlled Trial","PRO-CKD","Inclusion Criteria:\n\n* Adults aged ≥ 18 years (both males and females).\n* Diagnosed with Chronic Kidney Disease (CKD) Stage III or IV, confirmed by eGFR.\n* Stable medical condition with no recent hospitalization for acute kidney injury or other serious illnesses.\n* Not currently on probiotic supplementation or prebiotic therapy.\n* Willing to provide informed consent and comply with the study protocol, including clinic visits and sample collection.\n\nExclusion Criteria:\n\n* CKD Stage I, II, or V, or on dialysis.\n* Currently using probiotics or prebiotics as part of their diet or treatment.\n* History of active malignancy (cancer) or undergoing chemotherapy.\n* Significant gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome, or recent GI surgery).\n* Pregnant or breastfeeding women (due to safety concerns).\n* Patients with autoimmune diseases (e.g., lupus, rheumatoid arthritis).\n* Individuals on long-term antibiotic or anti-inflammatory medication that could interfere with microbiota composition.\n* Individuals with severe behavioral or cognitive disorders that may prevent adherence to the study protocol.",{"count":73,"type":20},72,[75,76],"PHASE1","PHASE2","The goal of this clinical trial is to learn whether probiotic supplementation can slow disease progression in patients with moderate to severe chronic kidney disease (CKD). The trial will also assess the safety of probiotics in these patients.\n\nThe main questions the study aims to answer are:\n\nDoes probiotic supplementation improve kidney function by reducing serum creatinine levels and protein in urine? Does it reduce inflammation and metabolic imbalances in CKD patients? Does it affect gut microbiota composition and lower harmful toxins in the body? Is probiotic supplementation safe and well-tolerated in CKD patients?\n\nParticipants will:\n\nBe randomly assigned to receive either probiotics or a placebo for 6 months. Have clinic visits every 6 months for checkups, blood tests, and urine tests. Be monitored for any side effects and changes in kidney function. Researchers will compare the probiotic group to the placebo group to determine whether probiotics are effective in slowing CKD progression.",[79,80,81,27],"Kidney Disease, Chronic","Renal Insufficiency, Chronic","Gut Dysbiosis",[83,84,85,27,86,87,88,89],"Chronic Kidney Disease (CKD)","Probiotics","Gut Microbiota","Indoxyl Sulfate (IS)","Inflammation in CKD","Dysbiosis in CKD","Lactobacillus plantarum","2025-05-13",{"date":92,"type":38},"2025-05-16",{"date":94,"type":38},"2025-04-03",{"date":96,"type":20},"2025-10-20",{"name":98,"class":45},"Mansoura University"]